Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 USD | +3.68% | +0.65% | +105.30% |
May. 14 | Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours | MT |
May. 14 | Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 210.5 | 1,851 | 419.3 | 330.6 | 766.2 | - | - |
Enterprise Value (EV) 1 | 210.5 | 1,851 | 419.3 | 330.6 | 766.2 | 766.2 | 766.2 |
P/E ratio | -50.9 x | -19.3 x | -4 x | -4.31 x | -11.3 x | -7.21 x | -6.89 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 928 x | 39.7 x |
EV / Revenue | - | - | - | - | - | 928 x | 39.7 x |
EV / EBITDA | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 17,988 | 217,788 | 218,393 | 218,944 | 247,171 | - | - |
Reference price 2 | 11.70 | 8.500 | 1.920 | 1.510 | 3.100 | 3.100 | 3.100 |
Announcement Date | 3/11/21 | 2/28/22 | 3/15/23 | 2/29/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 0.8252 | 19.29 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -32.1 | -43.55 | -93.32 | -119.7 | -99.82 | -101 | -169 | -171 |
Operating Margin | - | - | - | - | - | - | -20,473.39% | -886.45% |
Earnings before Tax (EBT) 1 | - | -41.66 | -86.85 | -104.2 | -75.8 | -76.5 | -144.4 | -152.2 |
Net income 1 | - | -64.28 | -86.85 | -104.2 | -75.8 | -76.5 | -144.4 | -152.2 |
Net margin | - | - | - | - | - | - | -17,500.88% | -789.02% |
EPS 2 | -0.1600 | -0.2300 | -0.4400 | -0.4800 | -0.3500 | -0.2740 | -0.4300 | -0.4500 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/20 | 3/11/21 | 2/28/22 | 3/15/23 | 2/29/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -29.61 | -28.19 | -37.87 | -29.34 | -24.34 | -26.52 | -26.13 | -26.34 | -20.83 | -20.2 | -22.36 | -29.01 | -32.58 | -41.1 | -46.9 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -25.13 | -21.29 | -34.86 | -27.2 | -20.84 | -21.73 | -20.64 | -19.65 | -13.79 | -14.79 | -16.67 | -21.24 | -24.36 | -35.7 | -41.5 |
Net income 1 | -25.13 | -21.29 | -34.86 | -27.2 | -20.84 | -21.73 | -20.64 | -19.65 | -13.79 | -14.79 | -16.67 | -21.24 | -24.36 | -35.7 | -41.5 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1200 | -0.1000 | -0.1600 | -0.1200 | -0.1000 | -0.1000 | -0.0900 | -0.0900 | -0.0600 | -0.0700 | -0.0560 | -0.0700 | -0.0780 | -0.1000 | -0.1100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/28/22 | 5/9/22 | 8/4/22 | 11/3/22 | 3/15/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/29/24 | 5/14/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | 0.15 | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/11/21 | 2/28/22 | 3/15/23 | 2/29/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+105.30% | 766M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- NUVB Stock
- Financials Nuvation Bio Inc.